Search
Now showing items 1-6 of 6
Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study
(MDPI, 2023-07-30)
Drug adherence is a significant medical issue, often responsible for sub-optimal outcomes during the treatment of chronic diseases such as rheumatoid or psoriatic arthritis. Monoclonal antibodies (which are exclusively ...
Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects
(MDPI, 2023-07-01)
Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but ...
Characterization and assessment of new fibrillar collagen inks and bioinks for 3D printing and bioprinting
(AccScience Publishing, 2023-03-16)
Collagen is a cornerstone protein for tissue engineering and 3D bioprinting due to its outstanding biocompatibility, low immunogenicity, and natural abundance in human tissues. Nonetheless, it still poses some important ...
Three-dimensional printing as a cutting-edge, versatile and personalizable vascular stent manufacturing procedure:Toward tailor-made medical devices
(WHIOCE, 2023)
Vascular stents (VS) have revolutionized the treatment of cardiovascular diseases, as evidenced by the fact that the implantation of VS in coronary artery disease (CAD) patients has become a routine, easily approachable ...
Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
(BMC, 2023-03)
In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects ...
Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior
(MDPI, 2023-11-13)
Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects ...